January 30, 2014

Novartis Consumer Health will be relaunching Theraflu for the 2014-2015 cough-cold season, Brian McNamara, Novartis division head OTC, told analysts.

January 14, 2014

Drug maker Sandoz has started a late-stage clinical trial of a biotech drug used to treat autoimmune disorders, the company said.

January 9, 2014

Novartis AG is reportedly in talks with Merck to swap its animal health and vaccines businesses for Merck’s OTC business, which includes the Coppertone sunscreen and Claritin allergy medicine brands, according to a Bloomberg report.

January 9, 2014

Mylan has launched a generic drug for preventing rejection of transplanted organs, the company said Thursday.

December 16, 2013

A drug made by Novartis extends the lives of patients with a life-threatening blood cancer to a greater extent than conventional therapy or placebo, according to results of a late-stage clinical trial.

December 9, 2013

Swiss drug maker Novartis is providing a vaccine to Princeton University amid an outbreak of potentially fatal meningitis that has affected at least eight students, the university said Monday.

December 2, 2013

Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

November 22, 2013

Sandoz has launched an authorized generic version of a topical drug for treating actinic keratosis, the company said.

November 22, 2013

Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

November 21, 2013

Teva has introduced a generic version of a drug used to treat attention deficit hyperactivity disorder, the company said Thursday.

November 18, 2013

Generic drug maker Mylan has launched its version of a drug for treating attention deficit hyperactivity disorder, the company said Monday.

November 11, 2013

Swiss drug maker Novartis is selling its blood transfusion diagnostics business to a Spanish manufacturer for $1.7 billion, Novartis said Monday.

October 15, 2013

The Food and Drug Administration has approved a new generic drug from Teva Pharmaceutical Industries for treating eye infections, the company said.

October 10, 2013

Such iconic pain relief brands as McNeil Consumer’s Tylenol and Motrin, and Novartis’ Excedrin, have made their way back to the shelf this fall following a recall-driven hiatus. And the sales have already started to accumulate.

September 23, 2013

Sandoz has launched an authorized generic drug for treating a disease commonly known as pre-leukemia, the company said on Monday.

September 10, 2013

One trend that generic companies and pharmacy retailers alike should keep an eye on is the patent cliff.

August 22, 2013

Novartis said Wednesday it would ship a "minimum" of 30 million doses of seasonal flu vaccine to customers in the United States this season.

August 20, 2013

Generic drug maker Sandoz has relaunched a website to promote its biosimilars business.

August 19, 2013

The Exchange, Safeway and Walmart were among the companies identified as the nation's top veteran-friendly companies by the U.S. Veterans Magazine last week.

August 8, 2013

Both Novartis Consumer Health and McNeil Consumer Healthcare will be making strong comebacks across their respective analgesic portfolios in the second half of this year, which will make a fourth-quarter battle royale across analgesics, as well as cough-cold.

August 2, 2013

The Food and Drug Administration has approved a vaccine against meningococcal disease for use among patients of a broader age range than before.

July 26, 2013

A federal court has ruled in favor of generic drug maker Sandoz in a case involving a drug for multiple sclerosis, Sandoz said.

July 22, 2013

The Food and Drug Administration has approved a drug made by Japanese drug maker Astellas for preventing the body from rejecting transplanted organs, the company said.

July 22, 2013

An announcement Monday by generic drug maker Sandoz gives a glimpse of what could happen in the United States when biosimilars start to become available.